LLY

1,083.67

+0.62%↑

JNJ

208.6

+0.53%↑

ABBV

231.27

+0.48%↑

UNH

329.18

-0.73%↓

AZN

92.74

-0.16%↓

LLY

1,083.67

+0.62%↑

JNJ

208.6

+0.53%↑

ABBV

231.27

+0.48%↑

UNH

329.18

-0.73%↓

AZN

92.74

-0.16%↓

LLY

1,083.67

+0.62%↑

JNJ

208.6

+0.53%↑

ABBV

231.27

+0.48%↑

UNH

329.18

-0.73%↓

AZN

92.74

-0.16%↓

LLY

1,083.67

+0.62%↑

JNJ

208.6

+0.53%↑

ABBV

231.27

+0.48%↑

UNH

329.18

-0.73%↓

AZN

92.74

-0.16%↓

LLY

1,083.67

+0.62%↑

JNJ

208.6

+0.53%↑

ABBV

231.27

+0.48%↑

UNH

329.18

-0.73%↓

AZN

92.74

-0.16%↓

Search

Certara Inc

Ouvert

SecteurSoins de santé

8.82 -0.68

Résumé

Variation du prix de l'action

24h

Actuel

Min

8.61

Max

8.87

Chiffres clés

By Trading Economics

Revenu

3.5M

1.5M

Ventes

46K

105M

P/E

Moyenne du Secteur

130.143

78.892

BPA

0.14

Marge bénéficiaire

1.458

Employés

1,487

EBITDA

-6.5M

23M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+41.28% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-428M

1.5B

Ouverture précédente

9.5

Clôture précédente

8.82

Sentiment de l'Actualité

By Acuity

94%

6%

359 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Certara Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 déc. 2025, 21:41 UTC

Acquisitions, Fusions, Rachats

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

28 déc. 2025, 23:57 UTC

Résultats

'Avatar: Fire and Ash' Tops Domestic Box Office Again -- Barrons.com

28 déc. 2025, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 déc. 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

28 déc. 2025, 23:48 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

28 déc. 2025, 10:30 UTC

Acquisitions, Fusions, Rachats

There's No Happy Ending for Movie Theaters, No Matter Who Wins Warner -- Heard on the Street -- WSJ

26 déc. 2025, 20:22 UTC

Market Talk

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

26 déc. 2025, 20:13 UTC

Market Talk

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

26 déc. 2025, 19:24 UTC

Acquisitions, Fusions, Rachats

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

26 déc. 2025, 17:45 UTC

Market Talk

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

26 déc. 2025, 15:52 UTC

Market Talk

Oil Futures Turn Lower After Steady Start -- Market Talk

26 déc. 2025, 14:58 UTC

Market Talk

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

26 déc. 2025, 14:41 UTC

Market Talk

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

26 déc. 2025, 14:28 UTC

Market Talk

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

26 déc. 2025, 13:47 UTC

Market Talk

Oil Futures Steady in Thin Holiday Trade -- Market Talk

26 déc. 2025, 07:22 UTC

Market Talk

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

26 déc. 2025, 05:03 UTC

Market Talk

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

26 déc. 2025, 03:38 UTC

Market Talk

Global Equities Roundup: Market Talk

26 déc. 2025, 03:38 UTC

Market Talk

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

26 déc. 2025, 02:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

26 déc. 2025, 02:44 UTC

Market Talk

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

26 déc. 2025, 01:39 UTC

Market Talk

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

26 déc. 2025, 01:14 UTC

Market Talk

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

26 déc. 2025, 00:34 UTC

Market Talk

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

26 déc. 2025, 00:15 UTC

Market Talk

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

25 déc. 2025, 23:42 UTC

Market Talk

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25 déc. 2025, 23:40 UTC

Market Talk

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25 déc. 2025, 00:20 UTC

Acquisitions, Fusions, Rachats

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24 déc. 2025, 22:22 UTC

Acquisitions, Fusions, Rachats

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24 déc. 2025, 21:26 UTC

Acquisitions, Fusions, Rachats

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

Comparaison

Variation de prix

Certara Inc prévision

Objectif de Prix

By TipRanks

41.28% hausse

Prévisions sur 12 Mois

Moyen 12.56 USD  41.28%

Haut 16 USD

Bas 9 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

6

Achat

5

Maintien

0

Vente

Score Technique

By Trading Central

11.27 / 12.79Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Very Strong Bullish Evidence

Long Terme

Strong Bullish Evidence

Sentiment

By Acuity

359 / 374Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat